- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Beacon Therapeutics Holdings Ltd.
Headquarters: London, United Kingdom
Website: https://www.beacontx.com/ab...
Year Founded: 2023
Status: Private
BioCentury | May 7, 2025
Product Development
PTC hits Huntington biomarker, but approval path still uncertain
Plus: Stock-driving data from Alphamab; hits and misses in retinal gene therapy; Celiac proof of concept data; and more
BioCentury | Aug 24, 2024
Management Tracks
ReAlta names David Marek CEO, Paolo Martini to lead R&D
Plus: Matthew Shaulis to leave Hansa, and updates from Beacon and The Genome Partnership
BioCentury | Jul 24, 2024
Management Tracks
Trimarchi becomes president, COO of BridgeBio
Plus: New CEO, CFO at Beacon and updates from enGene, Broken String and Nashville
BioCentury | Jul 16, 2024
Deals
Deals report: Ipsen gets second ADC; Context buys MSLN
Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships
BioCentury | Jul 12, 2024
Finance
Venture Report: With more company creation on tap, Flagship raises $3.6B
Plus: Big rounds for Element, Beacon and Myricx
BioCentury | Jun 18, 2024
Deals
Deals Report: Syncona merging Freeline, SwanBio to form Spur
Plus: AbbVie licenses TL1A mAb from FutureGen for IBD, and updates from Takeda, Ascentage, Pfizer, ProFound and more
BioCentury | Oct 19, 2023
Regulation
Oct. 18 Quick Takes: FDA approves UCB’s Bimzelx and Zilbrysq
Plus: After appeal, Ardelyx wins approval of kidney therapy, and updates from Mablink, Actym, Syncona, CDER and more
BioCentury | Jun 12, 2023
Emerging Company Profile
Syncona wraps up three ocular gene therapies, launches Beacon in second shot at XLRP
VCs back start-up in £96M series A, joining AGTC takeout with pair of preclinical programs
Items per page:
1 - 8 of 8